Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently develop...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dong Wook Kwak, Shin Young Kim, Hyun Jin Kim, Ji Hyae Lim, Young-Han Kim, Hyun Mee Ryu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c8dd70c1ea094b8a98d6e721f0060274
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c8dd70c1ea094b8a98d6e721f0060274
record_format dspace
spelling oai:doaj.org-article:c8dd70c1ea094b8a98d6e721f00602742021-12-02T15:32:59ZMaternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction10.1038/s41598-020-68842-12045-2322https://doaj.org/article/c8dd70c1ea094b8a98d6e721f00602742020-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-68842-1https://doaj.org/toc/2045-2322Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated HYP2 (m-HYP2) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-HYP2 levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-HYP2 levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (P < 0.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (P < 0.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (P < 0.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate.Dong Wook KwakShin Young KimHyun Jin KimJi Hyae LimYoung-Han KimHyun Mee RyuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Dong Wook Kwak
Shin Young Kim
Hyun Jin Kim
Ji Hyae Lim
Young-Han Kim
Hyun Mee Ryu
Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
description Abstract Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case–control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated HYP2 (m-HYP2) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-HYP2 levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-HYP2 levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (P < 0.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (P < 0.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (P < 0.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate.
format article
author Dong Wook Kwak
Shin Young Kim
Hyun Jin Kim
Ji Hyae Lim
Young-Han Kim
Hyun Mee Ryu
author_facet Dong Wook Kwak
Shin Young Kim
Hyun Jin Kim
Ji Hyae Lim
Young-Han Kim
Hyun Mee Ryu
author_sort Dong Wook Kwak
title Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
title_short Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
title_full Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
title_fullStr Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
title_full_unstemmed Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction
title_sort maternal total cell-free dna in preeclampsia with and without intrauterine growth restriction
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/c8dd70c1ea094b8a98d6e721f0060274
work_keys_str_mv AT dongwookkwak maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
AT shinyoungkim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
AT hyunjinkim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
AT jihyaelim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
AT younghankim maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
AT hyunmeeryu maternaltotalcellfreednainpreeclampsiawithandwithoutintrauterinegrowthrestriction
_version_ 1718387168917848064